H.C. Wainwright lowered the firm’s price target on IGM Biosciences to $17 from $22 and keeps a Buy rating on the shares post the Q2 report. The firm cites higher operating expenses as well as the company’s financings for the target drop.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IGMS:
- IGM Biosciences price target lowered to $17 from $31 at Baird
- IGM Biosciences price target lowered to $25 from $38 at Guggenheim
- IGM Biosciences reports Q2 EPS ($1.43), consensus ($1.43)
- IGM Biosciences Announces Second Quarter 2023 Financial Results
- Fly Insider: Children’s Place, Netflix among notable insider trades this week